RT Journal Article
SR Electronic
T1 Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2597
OP 2603
DO 10.21873/anticanres.15039
VO 41
IS 5
A1 KREJCI, DANIEL
A1 OPALKA, PETR
A1 KREJCI, JANA
A1 ZEMANOVA, MILADA
A1 ZEMANOVA, PETRA
A1 KULTAN, JURAJ
A1 FISCHER, ONDREJ
A1 SKRICKOVA, JANA
A1 BRATOVA, MONIKA
A1 CERNOVSKA, MARKETA
A1 HRNCIARIK, MICHAL
A1 COUPKOVA, HELENA
A1 HURDALKOVA, KAROLINA
A1 BARINOVA, MAGDA
A1 KOUBKOVA, LEONA
A1 DOLEZAL, DANIEL
A1 SAFANDA, MARTIN
A1 PESEK, MILOS
A1 SVATON, MARTIN
YR 2021
UL http://ar.iiarjournals.org/content/41/5/2597.abstract
AB Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non-small cell lung cancer (NSCLC) treatment. We conducted a real-world study to compare the outcomes of these chemotherapeutic regimens. Patients and Methods: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Results: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. Conclusion: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.